Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

iShares Global Healthcare ETF

100.64
-0.8300-0.82%
Volume:195.71K
Turnover:19.97M
Market Cap:4.24B
PE:-97.87
High:102.35
Open:101.97
Low:100.64
Close:101.47
52wk High:107.69
52wk Low:90.24
Shares:42.15M
Float Shares:42.15M
Volume Ratio:7.29
T/O Rate:0.46%
Dividend:1.44
Dividend Rate:1.43%
EPS(TTM):-1.0283
EPS(LYR):-1.0283
ROE:-8.66%
ROA:0.90%
PB:1.10
PE(LYR):-97.87

Loading ...

OverviewCompanyNewsFilings

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

MT Newswires Live
·
Sep 26

Innovation is Driving a New Bull Market in Biotech. 16 Ways to Play It, from Our Roundtable Experts.

Dow Jones
·
Sep 25

BioSyent Earns Spot on Canada’s Top Growing Companies 2026 List

TIPRANKS
·
Sep 25

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Sep 25

Johnson & Johnson Says Tremfya Significantly Improves Axial Psoriatic Arthritis Symptoms in Phase 4 Study

MT Newswires Live
·
Sep 25

Novo Bets on Next Chapter While Eli Lilly Extends Its GLP-1 Dominance

Deep News
·
Sep 25

Johnson & Johnson says Tremfya met endpoints in Phase 4 STAR study

TIPRANKS
·
Sep 25

J&J - Star Study Shows Tremfya Safety Profile Consistent with Psa; no New Safety Signals

THOMSON REUTERS
·
Sep 25

J&J - Tremfya Meets Primary Endpoint for Basdai Score Improvement at Week 24

THOMSON REUTERS
·
Sep 25

J&J - Tremfya Meets Primary and Major Secondary Endpoints in Axial Psa Study

THOMSON REUTERS
·
Sep 25

Johnson & Johnson Announces Tremfya® (Guselkumab) is the First and Only Il-23 Inhibitor to Show Significant Improvement in Spinal Pain and Stiffness in Landmark Axial Psoriatic Arthritis (Psa) Study

THOMSON REUTERS
·
Sep 25

Single Infusion of Carvykti Delivered Five-Year Treatment-Free Remissions in 50% of Patients in Early Line Relapsed/Refractory Multiple Myeloma

Reuters
·
Sep 25

Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant of Good Faith in License Agreement - SEC Filing

THOMSON REUTERS
·
Sep 25

J&J - Carvykti Delivers Five-Year Treatment-Free Remissions in 50% of Early Line Rrmm Patients

THOMSON REUTERS
·
Sep 25

J&J - Five-Year Overall Survival Rate 69.2%, Median Progression-Free Survival 60.5 Months

THOMSON REUTERS
·
Sep 25

FDA Approves Merck’s Welireg Plus Eisai’s Lenvima for Previously Treated Advanced Clear Cell Kidney Cancer

Reuters
·
Sep 25

Surrozen price target raised to $54 from $44 at H.C. Wainwright

TIPRANKS
·
Sep 25

Estee Lauder Cos. Cl a Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 25

Nanobiotix advances cancer nanotherapeutics and bolsters cash runway into 2029

TIPRANKS
·
Sep 25

Press Release: Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D. to Its Board of Directors

Dow Jones
·
Sep 25
More